Vertex Pharmaceuticals Incorporated
NASDAQVertex Pharmaceuticals enters the back half of June in a quiet but telling configuration — the stock is down nearly 1% on the week and off 75% over the past month, while options traders are quietly moving away from the defensive hedging that dominated through May. The clearest shift this week is in options sentiment. The put/call ratio has dropped to 0.81, sitting more than one…
Snapshot as of 22 Jun 2026
Vertex Pharmaceuticals enters the back half of June in a quiet but telling configuration — the stock is down nearly 1% on the week and off 75% over the past month, while options traders are quietly moving away from the…
VRTX heads into its Q1 2026 results — scheduled for May 13 — with options traders at their most defensive in months, even as the Street raised price targets and the lending market remains wide open. The clearest signal…
Vertex Pharmaceuticals arrives at its May 4 Q1 2026 earnings report carrying a 28.5% gap between where the stock trades and where most analysts believe it belongs. The bullish analyst thesis remains firmly intact…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRTX — free to start on ORTEX.
Sign up for free →Open VRTX on ORTEX